| |
|
Form Serial Number: |
DA20231215E00398
|
| 1.
Date of relevant event: |
12/12/2023
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
01548 |
| 4.
Name of listed corporation: |
Genscript Biotech Corporation |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
2,122,917,158 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Wang |
| (Other names) |
Luquan |
|
|
|
| 10.
Name of director (Chinese): |
王鲁泉 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1302 | There has been a change in nature of your interest in the shares because:
you have entered into an agreement for the sale of shares in which you are interested |
|
| 2201 | Interest of corporation controlled by you |
|
| 2201 | Interest of corporation controlled by you |
|
8,578,000 |
HKD |
|
|
18.2000 |
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 848,321,753 | 39.96 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 848,321,753 | 39.96 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| 2201 | Interest of corporation controlled by you |
| |
| 2401 | A concert party to an agreement to buy shares described in s.317(1)(a) |
| |
| 2202 | Interest of your spouse |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| Spouse | Huang Lili | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Zhang Fangliang | 5.12 | Y | |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Luquan | 22.76 | Y | |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Ye | 3.79 | Y | |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Zhang Fangliang | 21.34 | Y | |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Ye | 8.42 | Y | |
| Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Zhang Fangliang | 4.60 | Y | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| Zhang Fangliang | Addresses of individuals are not displayed. | 0 |
| Wang Ye | Addresses of individuals are not displayed. | 38,468,630 |
| Total number of shares in which a director is interested under sections 317 and 318 | 848,321,753 |
|
| |
| 34.
Supplementary information: |
As disclosed in the announcement of Genscript Biotech Corporation (the “Company”) dated 13 December 2023 (the “Announcement”), on 12 December 2023, Genscript Corporation and GNS II Holdings Limited (the “Purchaser”) entered into an agreement, pursuant to which Genscript Corporation has agreed to sell, and the Purchaser has agreed to purchase 8,578,000 shares of the Company, the completion of which is subject to a number of conditions. For details, please refer to the Announcement.
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
1
|
|
Date of filing this Form 3A: |
15/12/2023
(dd/mm/yyyy)
|
| |